15-12-2011

Trophos SA announced the results from the phase III study of Trophos’ lead compound, olesoxime, in 512 patients with ALS. Olesoxime did not demonstrate a significant increase in survival versus placebo in patients receiving riluzole (Rilutek(R)). A trend was seen on patients’ function as ...

more

12-12-2011

Takeda Pharmaceutical Company Limited announced that the European Commission has granted marketing authorisation for Edarbi® (azilsartan medoxomil), a new once-daily angiotensin receptor blocker (ARB) (also known as angiotensin II receptor antagonist [AIIRA]) for the treatment of essential ...

more

07-12-2011

Novartis will showcase more than one hundred and sixty presentations on data from its oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases. The CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) ...

more

18-11-2011

Bavarian Nordic A/S announced that its subsidiary, BN ImmunoTherapeutics has initiated the pivotal Phase 3 trial of PROSTVAC® for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol ...

more

Chronic steroid use to treat the symptoms of systemic juvenile idiopathic arthritis (SJIA) can contribute to slowed growth and delayed puberty

09-11-2011

Novartis announced new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) ...

more

21-10-2011

Teva Pharmaceutical Industries Ltd. and Active Biotech announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability ...

more

Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn’s disease

14-10-2011

Shield Therapeutics announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).“Following our successful fundraising in June, we are delighted to have now ...

more

20-09-2011

Takeda Pharmaceutical Company Limited announced that TAK-438 has entered into Phase III clinical trials in Japan for the treatment of patients with acid-related diseases such as reflux esophagitis.TAK-438, originated by Takeda, is a potassium-competitive acid blocker (P-CAB) that suppresses ...

more

Positive results from first pivotal immunogenicity Phase II/III trial in endemic region to prevent Japanese Encephalitis (JE) in children

19-09-2011

Intercell AG and its partner Biological E. Ltd. announced the successful completion of a pediatric Phase II/III study for the vaccine to protect children from Japanese Encephalitis (JE). Analysis of the pivotal Phase III safety and immunogenicity data showed positive results and that the ...

more

Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth

11-07-2011

Novartis announced that an interim analysis of a pivotal Phase III study showed Afinitor® (everolimus) tablets in combination with exemestane significantly extended progression-free survival (PFS), or time without tumor growth, when compared to placebo plus exemestane in women with advanced ...

more